Special aspects of interleukin-33 and the IL-33 receptor complex

Seminars in Immunology

Volumn 25, Issue 6, 2013, Pages 449-457

  Martin, Michael U ^a  

^a BFS Schubertstrasse 81   (Germany)

Author keywords

IL 33 receptor complex; IL 33 release; IL 33 signaling; Interleukin 33 processing; Intracellular IL 33

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; JANUS KINASE 2; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; STAT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

CELL CYCLE PROGRESSION; CELLULAR DISTRIBUTION; CELLULAR STRESS SIGNAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; ENDOTHELIUM CELL; GENE REGULATORY NETWORK; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; MAST CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; UPREGULATION;

AA; AMINO ACID; H; HUMAN; IL-1RACP; IL-33 RECEPTOR COMPLEX; IL-33 RELEASE; IL-33 SIGNALING; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN-33 PROCESSING; INTRACELLULAR IL-33; M; MOUSE;

CELL CYCLE CHECKPOINTS; CELL NUCLEUS; CHROMATIN; HUMANS; INFLAMMATION; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKINS; MAP KINASE SIGNALING SYSTEM; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION;

EID: 84892875505     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.10.006     Document Type: Review

References (108)

1. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
2. Onda H., Kasuya H., Takakura K., Hori T., Imaizumi T., Takeuchi T., et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999, 19:1279-1288.
3. Baekkevold E.S., Roussigné M., Yamanaka T., Johansen F.E., Jahnsen F.L., Amalric F., et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163:69-79.
4. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
5. Smith D.E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010, 40:200-208.
6. Kurowska-Stolarska M., Hueber A., Stolarski B., McInnes I.B. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011, 269:29-35.
7. Miller A.M. Role of IL-33 in inflammation and disease\\. J Inflamm (Lond) 2011, 8:22.
8. Mirchandani A.S., Salmond R.J., Liew F.Y. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012, 33:389-396.
9. + T cell responses. Science 2012, 335:984-989.
10. + T cells. Eur J Immunol 2011, 41:3351-3360.
11. Le H.T., Tran V.G., Kim W., Kim J., Cho H.R., Kwon B. IL-33 priming regulates multiple steps of the neutrophil-mediated anti-Candida albicans response by modulating TLR and dectin-1 signals. J Immunol 2012, 189:287-295.
12. Humphreys N.E., Xu D., Hepworth M.R., Liew F.Y., Grencis R.K. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008, 180:2443-2449.
13. Zhang L., Lu R., Zhao G., Pflugfelder S.C., Li D.Q. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 2011, 43:1383-1391.
14. Polumuri S.K., Jayakar G.G., Shirey K.A., Roberts Z.J., Perkins D.J., Pitha P.M., et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol 2012, 189:50-60.
15. Zhao W.H., Hu Z.Q. Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 2012, 58:267-273.
16. Ohno T., Morita H., Arae K., Matsumoto K., Nakae S. Interleukin-33 in allergy. Allergy 2012, 10.1111/all.12004.
17. Kunisch E., Chakilam S., Gandesiri M., Kinne R.W. IL-33 regulates TNF-α dependent effects in synovial fibroblasts. Int J Mol Med 2012, 29:530-540.
18. Meephansan J., Tsuda H., Komine M., Tominaga S.I., Ohtsuki M. Regulation of IL-33 expression by IFN-γ and tumor necrosis factor-α in normal human epidermal keratinocytes. J Invest Dermatol 2012, 10.1038/jid.2012.185.
19. Nomura K., Kojima T., Fuchimoto J., Obata K., Keira T., Himi T., et al. Regulation of interleukin-33 and thymic stromal lymphopoietin in human nasal fibroblasts by proinflammatory cytokines. Laryngoscope 2012, 122:1185-1192.
20. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106:9021-9026.
21. Kakkar R., Hei H., Dobner S., Lee R.T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012, 287:6941-6948.
22. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331.
23. Lüthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84-98.
24. Lunderius-Andersson C., Enoksson M., Nilsson G. Mast cells respond to cell injury through the recognition of IL-33. Front Immunol 2012, 3:82.
25. Russell S.E., Walsh P.T. Sterile inflammation - do innate lymphoid cell subsets play a role?. Front Immunol 2012, 3:246.
26. Haraldsen G., Balogh J., Pollheimer J., Sponheim J., Küchler A.M. Interleukin-33 - cytokine of dual function or novel alarmin?. Trends Immunol 2009, 30:227-233.
27. Lamkanfi M., Dixit V.M. IL-33 raises alarm. Immunity 2009, 31:5-7.
28. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104:282-287.
29. Roussel L., Erard M., Cayrol C., Girard J.P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008, 9:1006-1012.
30. Küchler A.M., Pollheimer J., Balogh J., Sponheim J., Manley L., Sorensen D.R., et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008, 173:1229-1242.
31. Sundlisæter E., Edelmann R.J., Hol J., Sponheim J., Küchler A.M., Weiss M., et al. The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol 2012, 181:1099-1111.
32. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 2011, 187:1609-1616.
33. Pichery M., Mirey E., Mercier P., Lefrancais E., Dujardin A., Ortega N., et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012, 188:3488-3495.
34. Hsu C.L., Bryce P.J. Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. J Immunol 2012, [Epub ahead of print] PubMed. PMID: 22922818.
35. Oboki K., Ohno T., Kajiwara N., Saito H., Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010, 59:143-160.
36. Talabot-Ayer D., Calo N., Vigne S., Lamacchia C., Gabay C., Palmer G. The mouse interleukin (IL) 33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J Leukoc Biol 2012, 91:119-125.
37. Hong J., Bae S., Jhun H., Lee S., Choi J., Kang T., et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem 2011, 286:20078-20086.
38. Talabot-Ayer D., Lamacchia C., Gabay C., Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009, 284:19420-19426.
39. Ali S., Nguyen D.Q., Falk W., Martin M.U. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 2010, 391:1512-1516.
40. Hayakawa M., Hayakawa H., Matsuyama Y., Tamemoto H., Okazaki H., Tominaga S. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun 2009, 387:218-222.
41. Lefrançais E., Roga S., Gautier V., Gonzalez-de-Peredo A., Monsarrat B., Girard J.P., et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 2012, 109:1673-1678.
42. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
43. Keller M., Rüegg A., Werner S., Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-831.
44. Gross O., Yazdi A.S., Thomas C.J., Masin M., Heinz L.X., Guarda G., et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36:388-400.
45. Ohno T., Oboki K., Kajiwara N., Morii E., Aozasa K., Flavell R.A., et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009, 183:7890-7897.
46. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
47. Tominaga S., Jenkins N.A., Gilbert D.J., Copeland N.G., Tetsuka T. Molecular cloning of the murine ST2 gene: characterization and chromosomal mapping. Biochim Biophys Acta 1991, 1090:1-8.
48. Klemenz R., Hoffmann S., Werenskiold A.K. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 1989, 86:5708-5712.
49. Yanagisawa K., Takagi T., Tsukamoto T., Tetsuka T., Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 1993, 318:83-87.
50. Mitcham J.L., Parnet P., Bonnert T.P., Garka K.E., Gerhart M.J., Slack J.L., et al. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. J Biol Chem 1996, 271:5777-5783.
51. Martin M.U., Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta 2002, 1592:265-280.
52. Boraschi D., Tagliabue A. The interleukin-1 receptor family. Vitam Horm 2006, 74:229-254.
53. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18.
54. Lingel A., Weiss T.M., Niebuhr M., Pan B., Appleton B.A., Wiesmann C., et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 2009, 17:1398-1410.
55. Schreuder H., Tardif C., Trump-Kallmeyer S., Soffientini A., Sarubbi E., Akeson A., et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997, 386:194-200.
56. Vigers G.P., Anderson L.J., Caffes P., Brandhuber B.J. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 1997, 386:190-194.
57. Thomas C., Bazan J.F., Garcia K.C. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 2012, 19:455-457.
58. Korherr C., Hofmeister R., Wesche H., Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol 1997, 27:262-267.
59. Wesche H., Korherr C., Kracht M., Falk W., Resch K., Martin M.U. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997, 272:7727-7731.
60. Ali S., Huber M., Kollewe C., Bischoff S.C., Falk W., Martin M.U. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007, 104:18660-18665.
61. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551-2555.
62. Palmer G., Lipsky B.P., Smithgall M.D., Meininger D., Siu S., Talabot-Ayer D., et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008, 42:358-364.
63. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011, 22:127-147.
64. Fekonja O., Bencina M., Jerala R. Toll/interleukin-1 receptor domain dimers as the platform for activation and enhanced inhibition of Toll-like receptor signaling. J Biol Chem 2012, [Epub ahead of print] PubMed PMID: 22829600.
65. Drube S., Heink S., Walter S., Löhn T., Grusser M., Gerbaulet A., et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010, 115:3899-3906.
66. Ashman L.K. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999, 31:1037-1051.
67. Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005, 23:16-43.
68. Rönnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004, 61:2535-2548.
69. Hu Z.Q., Zhao W.H., Shimamura T. Regulation of mast cell development by inflammatory factors. Curr Med Chem 2007, 14:3044-3050.
70. Migalovich-Sheikhet H., Friedman S., Mankuta D., Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol 2012, 3:238.
71. Duarte R.F., Franf D.A. The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma 2002, 43:1179-1187.
72. Lennartsson J., Shivakrupa R., Linnekin D. Synergistic growth of stem cell factor and granulocyte macrophage colony-stimulating factor involves kinase-dependent and -independent contributions from c-Kit. J Biol Chem 2004, 279:44544-44553.
73. Jahn T., Sindhu S., Gooch S., Seipel P., Lavori P., Leifheit E., et al. Direct interaction between Kit and the interleukin-7 receptor. Blood 2007, 110:1840-1847.
74. Marmiroli S., Bavelloni A., Faenza I., Sirri A., Ognibene A., Cenni V., et al. Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I. FEBS Lett 1998, 438:49-54.
75. Drube S., Schmitz F., Göpfert C., Weber F., Kamradt T. C-Kit controls IL-1β-induced effector functions in HMC-cells. Eur J Pharmacol 2012, 675:57-62.
76. Motshwene P.G., Moncrieffe M.C., Grossmann J.G., Kao C., Ayaluru M., Sandercock A.M., et al. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem 2009, 284:25404-25411.
77. Lin S.C., Lo Y.C., Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010, 17(465):885-890.
78. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
79. Kroeger K.M., Sullivan B.M., Locksley R.M. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol 2009, 86:769-778.
80. Flannery S., Bowie A.G. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol 2010, 80:1981-1991.
81. Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., et al. Tollip, a new component of the IL-1RI pathway, linksIRAK to the IL-1 receptor. Nat Cell Biol 2000, 2:346-351.
82. Moynagh P.N. The Pellino family: IRAK E3 ligases with emerging roles in innate immune signalling. Trends Immunol 2009, 30:33-42.
83. Faisal A., Saurin A., Gregory B., Foxwell B., Parker P.J. The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors. J Biol Chem 2008, 283:18591-18600.
84. Kollewe C., Mackensen A.C., Neumann D., Knop J., Cao P., Li S., et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 2004, 279:5227-5236.
85. Janssens S., Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003, 11:293-302.
86. Gottipati S., Rao N.L., Fung-Leung W.P. IRAK1: a critical signaling mediator of innate immunity. Cell Signal 2008, 20:269-276.
87. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
88. Funakoshi-Tago M., Tago K., Hayakawa M., Tominaga S., Ohshio T., Sonoda Y., et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 2008, 20:1679-1686.
89. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
90. Salmond R.J., Mirchandani A.S., Besnard A.G., Bain C.C., Thomson N.C., Liew F.Y. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol 2012, [Epub ahead of print].
91. Choi Y.S., Park J.A., Kim J., Rho S.S., Park H., Kim Y.M., et al. Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 2012, 421:305-311.
92. Wong C.K., Leung K.M., Qiu H.N., Chow J.Y., Choi A.O., Lam C.W. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS ONE 2012, 7:e29815.
93. Hochdörfer T., Kuhny M., Zorn C.N., Hendriks R.W., Vanhaesebroeck B., Bohnacker T., et al. Activation of the PI3K pathway increases TLR-induced TNF-α and IL-6 but reduces IL-1β production in mast cells. Cell Signal 2011, 23:866-875.
94. Mun S.H., Ko N.Y., Kim H.S., Kim J.W., Kim do K., Kim A.R., et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci 2010, 67:3883-3892.
95. Funakoshi-Tago M., Tago K., Sato Y., Tominaga S., Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-κB activation. Cell Signal 2011, 23:363-370.
96. Mori T., Miyamoto T., Yoshida H., Asakawa M., Kawasumi M., Kobayashi T., et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011, 23:701-712.
97. Pecaric-Petkovic T., Didichenko S.A., Kaempfer S., Spiegl N., Dahinden C.A. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009, 113:1526-1534.
98. Solari R., Smithers N., Kennard N., Ray K., Grenfell S. Receptor mediated endocytosis and intracellular fate of interleukin 1. Biochem Pharmacol 1994, 47:93-101.
99. Garlanda C., Anders H.J., Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009, 30:439-446.
100. Costelloe C., Watson M., Murphy A., McQuillan K., Loscher C., Armstrong M.E., et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem 2008, 105:1960-1969.
101. Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009, 182:2601-2609.
102. Moritz D.R., Rodewald H.R., Gheyselinck J., Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998, 161:4866-4874.
103. Jones S.A., Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002, 1592:251-263.
104. Nagata A., Takezako N., Tamemoto H., Ohto-Ozaki H., Ohta S., Tominaga S., et al. Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cell Mol Immunol 2012, 9:399-409.
105. Takezako N., Hayakawa M., Hayakawa H., Aoki S., Yanagisawa K., Endo H., et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006, 341:425-432.
106. Smeets R.L., van de Loo F.A., Joosten L.A., Arntz O.J., Bennink M.B., Loesberg W.A., et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum 2003, 48:2949-2958.
107. Smith D.E., Hanna R., Della Friend, Moore H., Chen H., Farese A.M., et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003, 18:87-96.
108. Liu X., Hammel M., He Y., Tainer J.A., Jeng U., Zhang L., et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A 2013, 110:14918-14923.